TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

11 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

11 studies on the map

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis — Johns Hopkins University, BaltimoreMitigation of Cardiovascular Disease Risks in Children With Extreme Obesity — University of Kentucky, LexingtonFood and Fitness With Medicine (FFWM) — Ohio State Healthy Community Center, ColumbusEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityInterleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease — Houston Methodist Research Institute, HoustonPeople With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists — Northwestern Memorial Hospital, ChicagoMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT — Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), TorranceEffects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults — University of Texas Health Science Center at San Antonio, San Antonio